StemCell Therapy

NEW YORK, Nov. 4, 2020 /PRNewswire/ --

Anti-Aging Market Research Report: By Product (Anti-Wrinkle, Hair Color, Ultraviolet Absorption, Anti-Stretch Mark), Treatment (Hair Restoration, Anti-Pigmentation, Adult Acne Therapy, Breast Augmentation, Liposuction, Chemical Peel), Demography (Generation X, Baby Boomers, Generation Y) - Global Industry Analysis and Growth Forecast to 2030

Read the full report: https://www.reportlinker.com/p05982459/?utm_source=PRN

The major driving factors for the anti-aging market are the rising number of awareness-raising seminars and conferences, surging geriatric population, increasing disposable income, technological advancements, expanding medical tourism sector, and escalating cosmetic surgery volume. These factors will lead to an increase in the industry revenue from $191.5 billion in 2019 to $421.4 billion in 2030, at an 8.1% CAGR during 20202030 (forecast period). Products used to diminish the signs of aging are easily available at physical stores and online portals.

A key factor aiding the anti-aging market advance is the rising number of seminars and conferences being organized to make plastic surgeons, students, and the general public about the advanced anti-aging treatments. For instance, the Aesthetic & Anti-Aging Medicine World Congress (AMWC) hosted by EuroMediCom (Informa Group) in April 2019 in Monte Carlo, Monaco, included five knowledge sharing and discussion sessions on anti-aging and aesthetics. Formerly, the Aesthetic & Anti-Aging Medicine World Congress 13th Edition was hosted in Thailand in September 2018 by the American Academy of Anti-Aging Medicine (A4M).

Another major reason the demand for anti-aging treatments and products is increasing is the booming geriatric population. The United Nations says that the number of people in the age group of 65 and above will surge from 703 million in 2019 to 1.5 billion by 2050. With age, people experience stem cell and fibrous tissue loss, which leads to dryness, wrinkles, sagging, and pigmentary alteration. Therefore, in order to continue looking young and attractive, the geriatric population regularly uses anti-aging remedies, which tighten and revitalize the skin, in addition to making people look young.

North America is the dominant region in the anti-aging market currently, owing to the rising plastic surgery volume and geriatric population. The UN expects the number of elderly people on the continent to increase to 96.2 million by 2050 from 59.9 million in 2019. This, coupled with the growing volume of plastic surgeries, is expected to result in a massive surge in the demand for various therapies and products that help people look young and aesthetically appealing.

Hence, as more people age and their awareness regarding how they can reverse or physically hide the effects of this process rises, the market will keep blossoming.

Read the full report: https://www.reportlinker.com/p05982459/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Read the original post:
Anti-Aging Market Research Report: By Product, Treatment, Demography - Global Industry Analysis and Growth Forecast to 2030 - PRNewswire

According to IMARC Groups latest report, titled Regenerative Medicine Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025,. Looking forward, IMARC Group expects the global regenerative medicine market to continue its strong growth during the next five years.

Regenerative medicine refers to a field of biomedical sciences involved in restoring the structure and function of damaged cells, organs, and tissues. It includes the study of stem cells that are developed in laboratories and then safely inserted into the human body to regenerate damaged bones, cartilage, blood vessels, and organs. Cellular and acellular regenerative medicines are widely adopted in various clinical therapeutic procedures, including cell therapies, immunomodulation, and tissue engineering. They have the potential to treat various chronic diseases, including Alzheimers, Parkinsons, cardiovascular disorders (CVDs), osteoporosis, spinal cord injuries, etc.

Request for a free sample copy of this report: https://www.imarcgroup.com/regenerative-medicine-market/requestsample

Market Trends

The rising prevalence of chronic diseases and genetic disorders is primarily driving the demand for regenerative medicine across the globe. Moreover, the growing geriatric population who are more prone to musculoskeletal, dermatological, and cardiological disorders is also augmenting the need for regenerative medicines. Furthermore, several technological advancements in cell-based therapies have led to the adoption of 3D bioprinting techniques and artificial intelligence (AI), thereby further propelling the market for regenerative medicine. Moreover, regenerative medicine decreases the risk of organ rejection by the body post-transplant and increases the patients recovery speed, thereby gaining traction in numerous organ transplantation procedures. The increasing investments in extensive R&D activities in the field of medical sciences are expected to drive the market for regenerative medicine.

Regenerative Medicine Market 2020-2025 Analysis and Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

The report has segmented the market on the basis of type, application, end user and region.

Breakup by Type:

Breakup by Application:

Breakup by End User:

Ask Analyst for Instant Discount and Download Full Report with TOC & List of Figure: https://bit.ly/2RAf08Y

Breakup by Region:

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact US:IMARC Group30 N Gould St, Ste RSheridan, WY 82801, USAWebsite: https://www.imarcgroup.com/Email: [emailprotected]USA: +1-631-791-1145Follow us on twitter: @imarcglobalLinkedin: https://www.linkedin.com/company/imarc-group

Originally posted here:
Regenerative Medicine Market 2020: Analysis, Top Companies, Size, Share, Demand and Opportunity To 2025 - Eurowire

DetailsCategory: DNA RNA and CellsPublished on Monday, 09 November 2020 18:03Hits: 291

NEW YORK, NY, USA I November 09, 2020 I Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the U.S. Food and Drug Administration (FDA) has lifted its clinical hold and cleared the Investigational New Drug (IND) Application to initiate a registrational study of AXO-AAV-GM2 gene therapy to treat patients with Tay-Sachs disease and Sandhoff disease. AXO-AAV-GM2 is the first investigational gene therapy to achieve IND clearance for Tay-Sachs and Sandhoff diseases. The Company received a letter from the FDA indicating that it has satisfactorily addressed all issues related to the clinical hold.

The IND clearance of AXO-AAV-GM2, the first potentially curative treatment for Tay-Sachs and Sandhoff diseases to enter the clinic, marks a seminal moment for the entire GM2 gangliosidosis community. Along with AXO-AAV-GM1 for GM1 gangliosidosis, todays announcement represents the second IND clearance for Axovants gene therapy pipeline in the last 12 months, said Gavin Corcoran, M.D., Chief R&D Officer of Axovant. AXO-AAV-GM1 and AXO-AAV-GM2 are the first gene therapies to enter active clinical development in their indications. Each program captures the essence of our mission to liberate patients from debilitating neurological diseases by rapidly advancing these gene therapy programs into clinical development. We look forward to working with our study investigators, academic partners, the patient community, and families to begin enrollment in the study promptly.

Sue Kahn, Executive Director of the National Tay-Sachs & Allied Diseases Association (NTSAD), added, This is a big step toward a potential therapy for the GM2 community. It has been a long journey since NTSAD started supporting this promising gene therapy research in 2006. We are thrilled that it is now entering the clinic, bringing tremendous hope to families and the entire NTSAD community.

Axovant aims to advance the program through strategic partnerships with leading research organizations. The Company recently announced a partnership with Viralgen, an AskBio subsidiary, to support AAV-based vector manufacturing of clinical trial material for the registrational study. Additionally, through an existing genetic testing collaboration with Invitae, ongoing partnership with GM2 gangliosidosis patient groups, and collaboration with leading academic researchers at the University of Massachusetts Medical School and Massachusetts General Hospital, Axovant expects to begin patient identification and site startup activities in preparation for dosing children in the planned clinical study.

AXO-AAV-GM2 is an investigational gene therapy for Tay-Sachs and Sandhoff diseases, which are rare, monogenic neurodegenerative lysosomal storage disorders caused by mutations in the genes that encode -Hexosaminidase A, HEXA and HEXB. Children affected by Tay-Sachs and Sandhoff diseases suffer from a progressively debilitating disease course and reduced life expectancy. AXO-AAV-GM2 delivers two vectors encoding the HEXA and HEXB genes directly to the central nervous system to produce a fully functional -Hexosaminidase A enzyme. In 2019, clinical evidence from two patients under an investigator-initiated study found that treatment with AXO-AAV-GM2 was generally well-tolerated and associated with improved bioactivity outcomes. In addition, the data demonstrated the attainment of normal neurodevelopmental milestones and improvement in myelination. AXO-AAV-GM2 has been granted Orphan Drug and Rare Pediatric Disease Designation by the FDA.

The study will enroll both infantile and juvenile subjects with GM2 gangliosidosis in the U.S. The two-part trial, sponsored by Axovant, will consist of (1) a dose ranging cohort evaluating the safe and efficacious dose of the gene therapy, followed by (2) an efficacy cohort, both of which form the basis of the registrational program. Terence R. Flotte, M.D., Professor of Pediatrics and Dean at the University of Massachusetts Medical School, will serve as principal investigator on the clinical trial.

About AXO-AAV-GM2

AXO-AAV-GM2 is an investigational gene therapy for GM2 gangliosidosis (also known as Tay-Sachs and Sandhoff diseases), a set of rare and fatal pediatric neurodegenerative genetic disorders caused by defects in theHEXA(leading to Tay-Sachs disease) orHEXB(leading to Sandhoff disease) genes that encode the two subunits of the -hexosaminidase A (HexA) enzyme. These genetic defects lead to progressive neurodegeneration and shortened life expectancy. AXO-AAV-GM2 aims to restore HexA function by introducing a functional copy of theHEXAandHEXBgenes via delivery of two co-administered AAVrh8 vectors.

About Axovant Gene Therapies

Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinsons disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit http://www.axovant.com.

In 2018, Axovant licensed exclusive worldwide rights from the University of Massachusetts Medical School for the development and commercialization of gene therapy programs for GM1 gangliosidosis and GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases.

SOURCE: Axovant Gene Therapies

Read more here:
Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff Diseases | DNA RNA and Cells | News...

PhoreMost Limited, the UK-based biopharmaceutical company and Oxford Biomedica plc (LSE:OXB) (Oxford Biomedica), a gene and cell therapy group, today announced that they have entered into a discovery collaboration to develop next-generation CAR-T cell therapies. Financial details of the agreement are not disclosed.

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, to identify therapeutic candidates for Oxford Biomedicas LentiVector gene therapy delivery system. The program will initially focus on CAR-T therapy and aims to develop next-generation cell therapies with significantly improved efficacy and durability.

Dr Chris Torrance, CEO, PhoreMost, said: This collaboration with Oxford Biomedica, a global pioneer in cell and gene therapies, is further recognition of the power of SITESEEKER, offering an exciting opportunity to discover and accelerate the development of clinical stage products. The natural complementarity between SITESEEKER and LentiVector offers great promise for this and future collaborations between the two companies.

John Dawson, CEO of Oxford Biomedica, said: We are excited to apply this next-generation technology to our LentiVector platform. The collaboration has the potential to deliver more effective CAR-T therapies, and we look forward to working closely with the PhoreMost team.

SITESEEKER exploits protein shape diversity to find functionally active peptides linked to any chosen disease setting, significantly enhancing the power of phenotypic screening and translation into therapeutic modalities. Based on proprietary protein interference, or PROTEINi, technology, SITESEEKER is able to systematically probe the entire proteome in a live cell environment to identify and exploit novel drug targets.

Oxford Biomedica is a world-leading pioneer of cell and gene therapies. Its LentiVector platform enables the successful development of breakthrough gene and cell-based medicines, and through collaborations with pharmaceutical partners, has delivered the first FDA and EMA approved CAR-T cell therapy.

View original post here:
PhoreMost and Oxford Biomedica Enter Gene Therapy Discovery Collaboration - Technology Networks

BOSTON and LONDON, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company is scheduled to present at the Barclays Gene Editing & Gene Therapy Summit on November 16, 2020 at 11:15 AM ET.

A live webcast of the presentation will be available under "News & Events" in the Investors & Media section of the company's website at http://www.orchard-tx.com. A replay of the webcast will be archived on the Orchard website following the presentation.

About Orchard

Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

Availability of Other Information About Orchard

Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Story continues

Contacts

Investors

Renee LeckDirector, Investor Relations+1 862-242-0764Renee.Leck@orchard-tx.com

Read more here:
Orchard Therapeutics to Present at Barclays Gene Editing & Gene Therapy Summit - Yahoo Finance

Final Report will add the analysis of the impact of COVID-19 on this industry.

November 2020:

The global Cell and Gene Therapy Market research report offers all the vital data in the domain. The latest report assists new bees as well as established market participants to analyze and predict the Cell and Gene Therapy market at the regional as well as global level. It covers the volume [k MT] as well as revenues [USD Million] of the global Cell and Gene Therapy market for the estimated period. Numerous key players Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., and MEDIPOST. are dominating the global Cell and Gene Therapy market. These players hold the majority of share of the global Cell and Gene Therapy market.

DownloadSamplecopy + All Related Graphs & Charts @: https://www.coherentmarketinsights.com/insight/request-sample/2475

The data presented in the global Cell and Gene Therapy market offers budding opportunities, which help users to make strategic moves and prosper their business. The report highlights the impact of numerous factors that might result in obstructing or propelling the Cell and Gene Therapy market at global as well as local level. The global Cell and Gene Therapy market research report offers the summary of key players dominating the market including several aspects such as their financial summary, business strategy, and most recent developments in these firms.

Detailed Segmentation:

By Therapy Type:Cell TherapyStem CellsT CellsDendritic CellsNK CellsTumor CellsGene TherapyGlobal Cell and Gene Therapy Market, By Indication:Cardiovascular DiseaseCancerGenetic DisorderInfectious DiseaseNeurological DisordersOthers

By Region

North America (U.S., Canada, Mexico)

Asia Pacific (India, China, Japan, South Korea, ASEAN, Rest of Asia Pacific)

Europe (Italy, Germany, France, Spain, Central & Eastern Europe, Rest of Europe)

Middle East & Africa (GCC, Turkey, Rest of the Middle East & Africa)

South America (Brazil, Argentina, Rest of South America)

The study encompasses profiles of major companies operating in the Cell and Gene Therapy Market. Key players profiled in the report includes: Amgen, Biogen, BioMarin Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, Novartis, Pfizer, Regeneron Pharmaceuticals and Sanofi, Spark Therapeutics, Agilis Biotherapeutics, Angionetics AVROBIO, Freeline Therapeutics, Horama, MeiraGTx, Myonexus Therapeutics, Nightstar Therapeutics, Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., and MEDIPOST.

Key points of the global Cell and Gene Therapy market

The oretical analysis of the global Cell and Gene Therapy market stimulators, products, and other vital facets

Recent, historical, and future trends in terms of revenue and market dynamics are reported

Pin-point analysis of the competitive market dynamics and investment structure is predicted to grow

Future market trends, latest innovations, and various business strategies are reported

Market dynamics include growth influencers, opportunities, threats, challenges, and other crucial facets

The global Cell and Gene Therapy market research report offers users with an all-inclusive package of market analysis that includes current market size, expansion rate, and value chain analysis. The global Cell and Gene Therapy market is segmented on a regional basis Europe, North America, Latin America, Asia Pacific, and Middle East & Africa as well. To offer a comprehensive view and competitive outlook of the global Cell and Gene Therapy market, our review team employs numerous methodological procedures, for instance, Porters five forces analysis.

This research report includes the analysis of various Cell and Gene Therapy market segments. The bifurcation of the global market is done based on its present and prospective inclinations. The regional bifurcation involves the present market scenario in the region along with the future projection of the global Cell and Gene Therapy market. The global market report offers an overview of expected market conditions due to changes in the technological, topographical, and economic elements.

Need a discount?

Note: *The discount is offered on the Standard Price of the report.

Ask for the discount @ https://www.coherentmarketinsights.com/insight/request-discount/2475

Questions answered in the report include

What is the expected market size by the end of the forecast period?

What are the major factors initiating the global Cell and Gene Therapy market growth?

What are the latest developments and trending market strategies that are influencing the growth of the Cell and Gene Therapy market?

What are the key outcomes of the Cell and Gene Therapy market developments?

Who are the key players in the market?

What are the opportunities and challenges faced by the key players?

Key Reasons for Purchasing Global Cell and Gene Therapy Market Report

New approaches and latest development trend that describe the structure of the market

Advanced market breakdown structure

Historical data and future market scope

In-depth market analysis based on statistics, growth stimulators, and market developments

Statistical data representation through figurative, numerical, and theoretical elaboration

Report provides insight of the business and sales activities

Why Coherent Market Insights:

Explore extensive library of market reports

Accurate and Actionable insights

Focus on Key Trends and Market Movements

Critical Consulting Project Execution

24/7 Online and Offline Support

Most-detailed market segmentation

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations

Promo-code: CMIFIRST1000

Buy This Complete A Business Report @:https://www.coherentmarketinsights.com/insight/buy-now/2475

NOTE:Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details

Interested about who is winning the race of COVID-19 Vaccine. Coherent Market Insights (CMI)

providesCOVID-19 Vaccine Trackerfor all the latest updates about COVID-19 Vaccine.

Customization of the Report:

If you do not think that you are looking into Artificial Pancreas Device Systems report or need any clear preconditions, please contact our custom research team at([emailprotected])

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Mr. ShahCoherent Market Insights1001 4th Ave,#3200Seattle, WA 98154Tel: +1-206-701-6702Email: [emailprotected]

Link:
Increase in the Adoption of Cell and Gene Therapy to Propel the Growth of the Cell and Gene Therapy Market Between 2020-2027 - Eurowire

The global Gene Therapy market is rife with several new opportunities for market growth. This study provides a comprehensive description of the various propensities and trends that are aiding the growth of this market. The review takes a holistic approach in analyzing and decrypting the various forces of market growth. The all-inclusive review covers multiple insights on the historic trends and future projections that have shaped the current fettle of the market. It is worthwhile to note that the review is written with careful evaluation of various outliers and exceptions to market growth. In order to reconcile the exceptions, the projections made in the review leave scope for scaling and optimization.

Get Sample Copy of this Report https://www.factmr.com/connectus/sample?flag=S&rep_id=4648

The global Gene Therapy Market is projected to reach a value of US$ XX Mn/Bn by the end of the forecast period. These projections are based on evidence-based research and analysis of the various parameters of market growth.

The global Gene Therapy market consists of the following key players:

The report takes a cognitive approach to decode the business strategies of each of the leading players. Besides, the report also gauges the impact of recent market developments on the growth trajectory of the global Gene Therapy market. The insights presented in the report are written after taking due cognizance of the various trends that currently exist in the industry.

The declaration of the coronavirus disease as a global health emergency, and successively a pandemic, created formidable challenges for the vendors within the global Gene Therapy market. The COVID-19 crisis caused a global economic downturn, aggravated by industrial shutdowns and supply chain disruptions. The vendors operating in the global Gene Therapy market are expected to make relentless efforts to minimize the damage caused by the pandemic over the coming years. Companies that deployed strategies of business continuity management and damage control were able to weather the storm. Therefore, COVID-19 pandemic has been a subjective crisis for various industries and players.

The report covers the following key regions:

Based on products, the Gene Therapy market can be segmented into the following categories:

A Customization of this Report is Available upon Request https://www.factmr.com/connectus/sample?flag=RC&rep_id=4648

The report gives an objective and pragmatic outlook on key trends pertaining to:

The report answers, in detail, the following key questions pertaining to market expansion:

The Gene Therapy market makes projections for the following phases:

Why Choose Fact.MR?

Fact.MR follows a multidisciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living across parts of the world with our 24/7 service availability.

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

Link:
Gene Therapy Market to Witness Marginal decline in Near Term amid COVID-19 Pandemic, Projects Fact.MR 2020 2026 - The Cloud Tribune

The large scale Exosome Therapeutic Market research report recognizes and analyses the emerging trends along with major drivers, challenges and opportunities in the market. Following aspects are kept into view while formulating this global Exosome Therapeutic Market report and include the market type, organization size, availability on-premises, end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific & Middle East & Africa. The market size, revenue generated from the sales and technologies by various application segments are also evaluated in this Exosome Therapeutic Market report. The report estimates 2020-2027 market development trends for industry.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in theExosome Therapeutic Marketreport areevox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global.Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:Corporatesales@databridgemarketresearch.com

Read more from the original source:
Exosome Therapeutic Market Is Set To Experience Revolutionary Growth || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International...

Analysis and discussion of important industry trends, market size, and market share are estimated in the Exosome Therapeutic Market report. This market research report identifies and analyses the emerging trends along with major drivers, restraints, challenges and opportunities in the market. Businesses can have an idea about complete background analysis of the industry which includes an assessment of the parental market. Furthermore, it works to determine the impact of buyers, substitutes, new entrants, competitors, and suppliers on the market. This global Exosome Therapeutic Market document takes into consideration diverse segments of the market analysis that todays business ask for.

Get Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&rp

Market Analysis and Insights:Global Exosome Therapeutic Market

Exosome therapeutic market is expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

The major players covered in theExosome Therapeutic Marketreport areevox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global.Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Get Full TOC, Tables and Figures of Market Report @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&rp

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

Based on source, the market is segmented into dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, urine and others. Mesenchymal stem cells are dominating in the market because mesenchymal stem cells (MSCs) are self-renewable, multipotent, easily manageable and customarily stretchy in vitro with exceptional genomic stability. Mesenchymal stem cells have a high capacity for genetic manipulation in vitro and also have good potential to produce. It is widely used in treatment of inflammatory and degenerative disease offspring cells encompassing the transgene after transplantation.

Based on therapy, the market is segmented into immunotherapy, gene therapy and chemotherapy. Chemotherapy is dominating in the market because chemotherapy is basically used in treatment of cancer which is major public health issues. The multidrug resistance (MDR) proteins and various tumors associated exosomes such as miRNA and IncRNA are include in in chemotherapy associated resistance.

Based on transporting capacity, the market is segmented into bio macromolecules and small molecules. Bio macromolecules are dominating in the market because bio macromolecules transmit particular biomolecular information and are basically investigated for their delicate properties such as biomarker source and delivery system.

Based on application, the market is segmented into oncology, neurology, metabolic disorders, cardiac disorders, blood disorders, inflammatory disorders, gynecology disorders, organ transplantation and others. Oncology segment is dominating in the market due to rising incidence of various cancers such as lung cancer, breast cancer, leukemia, skin cancer, lymphoma. As per the National Cancer Institute, in 2018 around 1,735,350 new cases of cancer was diagnosed in the U.S. As per the American Cancer Society Inc in 2019 approximately 268,600 new cases of breast cancer diagnosed in the U.S.

Based on route of administration, the market is segmented into oral and parenteral. Parenteral route is dominating in the market because it provides low drug concentration, free from first fast metabolism, low toxicity as compared to oral route as well as it is suitable in unconscious patients, complicated to swallow drug etc.

The exosome therapeutic market, by end user, is segmented into hospitals, diagnostic centers and research & academic institutes. Hospitals are dominating in the market because hospitals provide better treatment facilities and skilled staff as well as treatment available at affordable cost in government hospitals.

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Customization Available:Global Exosome Therapeutic Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-exosome-therapeutic-market&rp

About Data Bridge Market Research :

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Mail:[emailprotected]

See the rest here:
Exosome Therapeutic Market Analysis over Numerous Prominent || Major Gaints Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,...

The Penn Medicine team identified 18 genetic variants that are related to either heavy alcohol consumption, alcohol use disorder, or both. Five of these variants overlapped, while eight were associated solely with heavy alcohol consumption. Another five were traced with alcohol use disorder only.

One finding from the study was that, although heavy drinking is a prerequisite for alcoholism, variants for particular genes may predispose someone towards alcoholism. Examples of gene variants cited by the Penn Medicine researchers are DRD2 and SIX3. This finding is important because identifying these gene variants in a person may help medical professionals better ascertain their risk for alcohol use disorder.

Ultimately, paying attention to the genetic aspect of a persons alcohol use disorder may contribute to their treatment. There are ongoing studies about patients receptiveness to certain medications for treatment, based on their genes.

For example, naltrexone is a drug thats commonly used to treat dependence on alcohol, as well as opiates. In research cited by the NIAAA, it was found that patients with a specific gene variation responded positively to naltrexone treatment. Those who didnt have the gene, however, did not. In the future, this kind of information may factor into the accuracy and responsiveness of medical treatment for alcohol addiction.

Conclusion: Unlocking Important New Knowledge about Genetics and Alcohol Addiction

Though the relationship between genes and alcoholism has been under scrutinous scientific study for some time, it isnt always common knowledge to laymen. But not being able to see the bigger picture of what contributes to alcoholism may allow certain myths about it to prevail. Many people may still believe that alcohol addiction is 100% a personal choice. But as the information above about genetics and alcohol use disorder portray, its never that simple.

In any case, whether genes influence someones predisposition to alcohol use disorder, no attempt at healing from it is a futile one. Be both compassionate and knowledgeable when approaching the issue of alcoholismbecause your support could save a life.

The rest is here:
Genetics and Alcohol Use Disorder: 5 Things You Should Know - Longevity LIVE

The report on the Global Adrenomyeloneuropathy Treatment Market has been prepared after conducting a comprehensive research through a systematized methodology. These skills are useful for scrutinizing the market on the terms of outlined research guidelines. Mainly, global Adrenomyeloneuropathy Treatment market research report covers all the information about the target audience, manufactures, vendors, research papers, products and many more. Keeping a focus on the overall market aspects, and perceptions, this report vastly covers profiles of the companies who have made it big in this particular field along with their sales data and other data. It also suggests the business models, innovations, growth and every information about the big manufacturers that will be present the future market estimates. Every market consists of set of manufacturers, vendors and consumers that gives a definition to the market, its each and every move, achievements. All these are the important subjects required to study the analysis of the global Adrenomyeloneuropathy Treatment market.

Get sample copy of Adrenomyeloneuropathy Treatment Market report @ https://www.orbispharmareports.com/sample-request/44669

It also includes the major market conditions across the globe such as the product profit, price, production, capacity, demand, supply, as well as market growth structure. In addition, this report offers significant data through the SWOT analysis, investment return data, and investment feasibility analysis. The global Adrenomyeloneuropathy Treatment market report also features a comprehensive quantitative and qualitative evaluation by analysing information collected from market experts and industry participants in the major points of the market value chain.

Major Company Profiles operating in the Adrenomyeloneuropathy Treatment Market:

Ascend BiopharmaceuticalsImmatics BiotechnologiesHuman LongevityNovadip BiosciencesBioRestorative TherapiesEureka TherapeuticsCytori TherapeuticsAllogene TherapeuticsRegeneusNewLink GeneticsTalaris Therapeutics

By the product type, the market is primarily split into:

Steroid Replacement TherapyStem Cell Transplant

By the application, this report covers the following segments:

HospitalsClinicsAmbulatory Surgical CentersOthers

The data offered in global Adrenomyeloneuropathy Treatment market report is gathered based on the latest industry news, trends, as well as opportunities. This study offers a separate analysis of the major trends in the existing market, mandates and regulations, micro macroeconomic indicators is also comprised in this report. By doing so, the study estimated the attractiveness of every major segment during the prediction period.

Browse the complete report @ https://www.orbispharmareports.com/covid-19-impact-on-2020-2026-global-and-regional-adrenomyeloneuropathy-treatment-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report-standard-version/

Moreover, the report comprises the analysis of opportunities available in the Adrenomyeloneuropathy Treatment market on the global level. It also includes the major market conditions across the globe such as the product profit, price, production, capacity, demand, supply, as well as market growth structure. The annual progression for the global Adrenomyeloneuropathy Treatment market in different regions cannot always be listed down as it will keep changing, thus studying and reviewing markets occasionally becomes vital.

In addition, the Adrenomyeloneuropathy Treatment market report provides a detailed information about the key market players along with the strategies they implemented to gain market existence and develop themselves. The report includes precise market estimations depending on current market status and future market forecasts.

For Any Query on the Adrenomyeloneuropathy Treatment Market: https://www.orbispharmareports.com/enquiry-before-buying/44669

About Us :

At Orbispharma we curate the most relevant news stories, features, analysis and research reports on the important challenges undertaken by the pharmaceutical and related sectors. Our editorial philosophy is to bring you sharp, focused and informed perspective of industries, the end users and application of all upcoming trends into the pharma sector. Orbispharma believes in conversations that can bring a change in one of the most crucial economic sectors in the world. With these conversations we wish our customers to make sound business decisions with right business intelligence.

Contact Us :

4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.+1 (972)-362-8199[emailprotected]

See original here:
Adrenomyeloneuropathy Treatment Market Covid-19 Impact On In-depth Industry Analysis: Ascend Biopharmaceuticals, Immatics Biotechnologies, Human...

There are millions of them around the globe waiting for clutching on to some of the latest vital information circulating across the globe. The up-to-the-minute AI Medicine Software market report based on the growth and the development of theAI Medicine Software marketis systematically listed down. The AI Medicine Software market report comprises statistically verified facts such the unique essence including topological investigations, worldwide market share, government stringent norms, applications, current trends, futuristic plans, market bifurcations, and so on mentioned in a crystal clear pattern.

The statistical plus scientific AI Medicine Software market report has all the important market aspects penciled down in a layman language format so that the data based on the markets productivity or future strategy can be easily extrapolated from the reports. The AI Medicine Software market report has the dominant market players Tempus Labs, Inc., Flatiron Health, Inc., Gene42, Inc., Sunquest Information Systems Inc, 2bPrecise LLC, NantHealth, Inc, IBM Watson Group, Human Longevity, Inc., N-of-One, Inc., Translational Software, Inc, SOPHiA GENETICS SA, Syapse, Inc., LifeOmic Heal explained in detail.

Sample of global AI Medicine Software Market Report at::https://www.marketresearchstore.com/report/global-ai-medicine-software-market-report-2020-industry-761259#RequestSample

The essential futuristic segments such as {Machine Learning, Natural Language Processing, Others}; {Drug Discovery, Precision Medicine, Others} have also been detailed out in the AI Medicine Software market report for the clients convenience and more of vital data embracing capability. The forecast trends along with the current market status can better understand the AI Medicine Software market development on a global basis. The intricate industrial strategies and the supply-demand chain are also discussed in the contextual report.

Key points of the global AI Medicine Software market

Theoretical analysis of the global AI Medicine Software market stimulators, products, and other vital facets Recent, historical, and future trends in terms of revenue and market dynamics are reported Pin-point analysis of the competitive market dynamics and investment structure is predicted to grow Future market trends, latest innovations, and various business strategies are reported Market dynamics include growth influencers, opportunities, threats, challenges, and other crucial facets

The AI Medicine Software market report has the imperative data mentioned in a systematic way only after comprehensive inspection and vigilant referencing. The diagrammatic representations such as a pie chart of the AI Medicine Software market are also drawn out so as to attract the punters and make it easy for them to comprehend the entire AI Medicine Software market from in and out. The most eye-catching format of the AI Medicine Software market report is its market bifurcation based on the product type, application, geography, end-users, and more as per the particular market. The geographical segments Europe, North America, Latin America, Asia Pacific, and Middle East & Africa are further exhaustively mentioned.

Read Detailed Index of full Research Study at::https://www.marketresearchstore.com/report/global-ai-medicine-software-market-report-2020-industry-761259

Questions answered in the report include

1. What is the expected market size by the end of the forecast period?2. What are the major factors initiating the global AI Medicine Software market growth?3. What are the latest developments and trending market strategies that are influencing the growth of the AI Medicine Software market?4. What are the key outcomes of the AI Medicine Software market developments?5. Who are the key players in the market?6. What are the opportunities and challenges faced by the key players?

The AI Medicine Software market report endows the global market dominance, market segmentation, growth factors, and others reported such that the clients can have a total tour of the market without any much off efforts needed.

Key Reasons for Purchasing Global AI Medicine Software Market Report

New approaches and latest development trend that describe the structure of the market Advanced market breakdown structure Historical data and future market scope In-depth market analysis based on statistics, growth stimulators, and market developments Statistical data representation through figurative, numerical, and theoretical elaboration Report provides insight of the business and sales activities

Ask Any Kind of Query Before Purchasing the Report Here:https://www.marketresearchstore.com/report/global-ai-medicine-software-market-report-2020-industry-761259#InquiryForBuying

View post:
Global AI Medicine Software Market Analysis of Key Players, Type, Application, Demand and Consumption By 2026 - Stock Market Vista

Global Obesity Treatment Market: Overview

Obesity is a disorder in which excess body fat gets accumulated to such extent that it may have negative effects on health. It occurs over time when people eat more calories than they utilize. The reasons for obesity can be medical problems, inactivity, genetics, family lifestyle, unhealthy diet, medications, age, and pregnancy. Being obese increases the risk of diabetes, heart disease, stroke, arthritis, and some type of cancers.

Obesity treatment basically incorporates a two-step process: assessment and management. Obesity assessment includes determination of the level of obesity and obesity management involves overall maintenance of body weight as well as the systematic weight loss programs.Government initiatives to increase the awareness about fitness, technological advancements improving the compliance rates of surgeries, and aggressive marketing strategies to attract customers are some of the drivers for the growth of the obesity treatment market.

Factors responsible for restraining the growth of the obesity treatment market are availability of low cost alternatives, high cost of customization, and post-surgical side effects.

Request Brochure for Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=18497

Global Obesity Treatment Market: Notable Developments

The obesity treatment market is segmented based on lifestyle changes, surgical & implant devices, and medication therapy. Lifestyle changes involves dietary changes and exercise. The dietary segment held a significant share in 2015 and is expected to increase during the forecast period. The reasons for the projected growth of the segment might be low cost of therapy, increase in health consciousness among people, and acceptance of the fact that it is easier to lower calorie intake to a greater degree than to burn more calories through increased exercise.

The surgery & implant devices are further categorized into gastric bypass surgery, gastric balloon, gastric band, electrical stimulation system, and gastric emptying system. Gastric bypass surgery is a fast growing segment in the obesity treatment market owing to factors such as fast recovery time, improved psychological status, and improved longevity. The minimally invasive segment is expected to grow at a higher rate during the forecast period due to its reversible nature, rapid effect, and cost & time effectiveness. It basically involves employing the implant devices in gastric area, which minimizes the incidences of post-operative infections that arise from invasive procedures. It in turn shortens the hospital stays for patients.

Request for Analysis of COVID19 Impact on Obesity Treatment Market:

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=18497

Global Obesity Treatment Market: Key Trends

The surgery & implant devices are further categorized into gastric bypass surgery, gastric balloon, gastric band, electrical stimulation system, and gastric emptying system. Gastric bypass surgery is a fast growing segment in the obesity treatment market owing to factors such as fast recovery time, improved psychological status, and improved longevity. The minimally invasive segment is expected to grow at a higher rate during the forecast period due to its reversible nature, rapid effect, and cost & time effectiveness. It basically involves employing the implant devices in gastric area, which minimizes the incidences of post-operative infections that arise from invasive procedures. It in turn shortens the hospital stays for patients.

In medication therapy, the individual (satiety) drug and combination drug therapy are the two major segments. The combination drug segment in the obesity treatment market captured a large share globally in 2015. It is mainly attributed to the synergistic effect of combined therapy in obesity treatment and rising prevalence of obesity. The satiety drug which provide a feeling of gastric fullness is a fast growing segment in the obesity treatment market. The major reason for the growth is its cost which is lower than that of the combination therapy.

Key Players of Obesity Treatment Market Report

Key market players operating in the obesity treatment market include NutriSystem, Inc. (U.S.), Kellogg Company (U.S.), Ethicon, Inc. (U.S.), Atkins Nutritionals, Inc. (U.S.), Herbalife Ltd. (U.S.), Covidien plc (U.S.), Apollo Endosurgery (U.S.), Amer Sports (Finland), Johnson Health Technology, Ltd. (Taiwan), Cybex International (U.S.), Olympus Corporation (Japan), Brunswick Corporation (U.S.), and Technogym SpA (Italy). Increase in focus of the market players on gaining FDA approvals to launch new drugs and devices in the obesity treatment market propels the growth of the obesity treatment market exponentially during the forecast period.

Buy Obesity Treatment Market Report

https://www.transparencymarketresearch.com/checkout.php?rep_id=18497&ltype=S

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Continued here:
Global Obesity Treatment Market Incredible Potential Examined in New Research Report - The Think Curiouser

New Market Research Report: on Adrenomyeloneuropathy Treatment Market size | Segment by Applications (Hospitals, Clinics, Ambulatory Surgical Centers and Others), by Type (Steroid Replacement Therapy and Stem Cell Transplant), Regional Outlook Opportunity, Market Demand, Latest Trends, Adrenomyeloneuropathy Treatment Industry Share & Revenue by Manufacturers, Leading Companies Profiles, Analysis, Growth Forecast 2025. Analyzes current market size and upcoming Few years' growths of this industry.

Adrenomyeloneuropathy Treatment Market Size report is the best source that gives CAGR values with variations during the forecast period of 2020-2025 for the market. The study encompasses market drivers and restraints by using SWOT analysis, along with their impact on the demand over the forecast period. This global market report endows with a profound overview of product specification, product type, production analysis, and technology by taking into consideration the major factors such as revenue, cost, and gross margin. The Adrenomyeloneuropathy Treatment advertising report has been prepared based on the market type, size of the organization, availability on-premises, and the end-users organization type.

Some of the prominent players operating in the global Adrenomyeloneuropathy Treatment market include Ascend Biopharmaceuticals, Immatics Biotechnologies, Human Longevity, Novadip Biosciences, BioRestorative Therapies, Eureka Therapeutics, Cytori Therapeutics, Allogene Therapeutics, Regeneus, NewLink Genetics and Talaris Therapeutics among others.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/240610

Competitive Analysis: Adrenomyeloneuropathy Treatment Market

Global Adrenomyeloneuropathy Treatment market Size is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Adrenomyeloneuropathy Treatment market Share for global, Europe, North America, Asia-Pacific, South America, and Middle East & Africa.

Global Adrenomyeloneuropathy Treatment Market Split by Product Type and Applications:

Based on Types:

Based on Application:

The latest research on the Adrenomyeloneuropathy Treatment Market Size fundamentally delivers insights that can empower stakeholders, business owners, and field marketing executives to make effective investment decisions driven by facts and extremely thorough research. The study aims to provide an evaluation and deliver essential information on the competitive landscape to meet the unique requirements of the companies and individuals operating in the Adrenomyeloneuropathy Treatment Market for the forecast period, 20202025. To help firms comprehend the Adrenomyeloneuropathy Treatment industry in multiple ways, the report exhaustively assesses the share, size, and growth rate of the business worldwide.

Report Highlights:

The report covers the shifting industry dynamics

Detailed information about the market segmentation

Covers past, present and projected industry size Recent industry trends

Key Competition landscape

Business strategies of key players and product offerings

Potential and niche segments/regions exhibiting promising growth

A neutral perspective towards market performance

Queries Resolved In This Report:

Which will be the specialties at which Adrenomyeloneuropathy Treatment Market players profiling with intensive designs, financials, and ongoing headways should set nearness?

Which will be the foreseen development rates for your own Adrenomyeloneuropathy Treatment economy out and out and each portion inside?

Which will be the Adrenomyeloneuropathy Treatment application and sorts and estimate joined intently by makers?

Which will be the dangers which will attack growth?

The length of the global Adrenomyeloneuropathy Treatment market opportunity?

How Adrenomyeloneuropathy Treatment Market share advance vacillations of their value from various assembling brands?

Chapters Define in TOC (Table of Content) of the Report:

Chapter 1: Market Survey, Drivers, Restraints and Good fortune, Segmentation overview

Chapter 2: Market competitiveness by Manufacturers

Chapter 3: Production by Regions

Chapter 4: Consumption by Regions

Chapter 5: Production, By Types, Revenue and Market share by Types

Chapter 6: Consumption, By Applications, Market share (%) and Growth Rate by Applications

Chapter 7: Overall profiling and analysis of Manufacturers

Chapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses

Chapter 9: Supply Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Market Influence Factors Analysis

Chapter 12: Market Predict

Chapter 13: Adrenomyeloneuropathy Treatment Research Findings and Conclusion, Appendix, methodology and data source

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/240610

Go here to see the original:
Global Adrenomyeloneuropathy Treatment Market Size, Share, Trends, CAGR by Technology, Key Players, Regions, Cost, Revenue and Forecast 2020 to 2025 -...

Jocelyn Aguilar felt bad enough after the first of a scheduled four rounds of chemotherapy that she thought about quitting.

She had no detectable cancer after undergoing double mastectomy for breast cancer, so the chemotherapy was an optional treatment that Aguilar, age 37 when diagnosed in October 2019, had chosen to reduce the risk of recurrence.

She ultimately decided to continue because, starting with her next round of chemotherapy, she was going to help test a counterintuitive-but-promising strategy for reducing chemotherapys side effects and increasing its cancer-fighting power: a very low-calorie diet designed to mimic the effects of fasting.

On weeks (when) I was due to receive chemo that Friday, I got four boxes of food labeled Tuesday, Wednesday, Thursday and Friday. The only food I ate those days came from that days box. On Saturday morning, I woke up and eased myself back into normal eating, says Aguilar, a nurse who works at the University of Southern California (USC), where the trial took place.

The pain I experienced with that first round of chemo, before the fasting, was so terrible that I didnt think I could go on, says Aguilar, who described the sensation as aches and pains all over her body. With the fast, there were still some effects, but they were not nearly as bad. It was a huge difference.

Aguilar says that her food boxes each contained about 300 calories worth of plant-based food. The diet is billed by its distributor as containing micro- and macronutrients that are nourishing but not recognized as food by the body, which mimics fasting.

Its hard to imagine a more counterintuitive cancer treatment than fasting why deprive the body of vital nutrients when it would seem to need them most? but a growing body of research suggests that fasting decreases the toxicity of cancer treatments and may increase their efficacy too.

Some evidence also shows that a ketogenic diet, which deprives the body of carbohydrates rather than all calories, may increase the efficacy of some cancer treatments. In fact, there is even some thought that the two diets may help prevent cancer, although evidence for this is currently limited.

When it comes to supplementing cancer therapies, the benefits of either dietary intervention also have yet to be definitively proven unless youre a mouse. The animal data for fasting, which started in our lab but is now coming from many labs, is extraordinary. Its hard to think of anything in the past, ever, that has done better, says Valter Longo, who holds a doctorate in biochemistry and is the Edna M. Jones Professor of Gerontology and Biological Sciences and the director of the Longevity Institute at the USC Leonard Davis School of Gerontology.

Healthy cells and tumor cells respond differently to fasting. Healthy cells shut down their growth-promoting pathways shortly after the food stops coming in and focus on cell repair. Cancer cells, on the other hand, rarely slow their unrestrained growth enough to engage in this self-protective behavior.

Fasting thus increases the ability of healthy cells to withstand stressors such as chemotherapyor radiotherapy, but it leaves cancer cells, which suddenly have less nutritional support to sustain their rapid growth, unusually weak and vulnerable.

Fasting also depletes stored carbohydrates. Normal cells can adapt to this by running mostly on two fat-derived energy sources fatty acids and ketones but cancer cells are far more reliant on sugars, starches and the insulin that drives them into cells.

Most of the mouse studies to date have assessed fastings effect on chemotherapy or radiotherapy, but at least one study has found that a low-calorie fasting- mimicking diet (FMD) plus simple vitamin C can slow the progression of KRAS-mutated colon cancer. Another study, this one published in the prestigious journal Nature, found that both fasting and a FMD increased and extended the efficacy of the hormonal treatments tamoxifen and Faslodex (fulvestrant) in mouse models of hormone-receptor-positive breast cancer.

The first clinical trial of short-term fasting in humans, which was published in 2009, reported results in 10 patients with various types of cancer. It found that fasting reduced chemotherapy-related toxicities fatigue, weakness and gastrointestinal side effects in the six patients who fasted 48 to 140 hours before and five to 56 hours after some (but not all) of their chemotherapy sessions.

Several other trials in humans, all of them following small patient populations for short periods of time, have also found that fasting reduced treatment-related toxicities such as fatigue or DNA damage in healthy cells. For example, one Dutch trial assigned six patients with breast cancer to follow normal dietary guidelines and seven others to fast 24 hours before and after chemotherapy. Nonhematological toxicity did not differ between the two groups, but the researchers found evidence that fasting reduced bone marrow toxicity and reduced chemotherapy-induced DNA damage in some healthy blood cells.

Data from several of these small trials also suggested that fasting increased treatment efficacy, but none of them were large enough (or lasted long enough) to prove that fasting extended patients survival. There is even less evidence to support the use of fasting or the ketogenic diet in combination with immunotherapy treatments, although that remains a tantalizing possibility.

The only large trial in humans to have reported results so far was inconclusive for a somewhat unexpected reason.

Investigators randomly assigned 131 Dutch women, all of whom were slated to receive chemotherapy for stage 2/3 HER2-negative breast cancer, either to eat according to standard guidelines or to follow the FMD. Sixty-six of the women were assigned to follow the FMD but, unfortunately, so few actually complied that it was impossible to evaluate the diets effects. Just 32% of women in the fasting group fasted before at least half of their chemotherapy cycles, and just 24% of them fasted before all of them.

Patient noncompliance was particularly disappointing because the FMD was designed by Longo who has a financial interest in a company that sells FMD meal kits as a less demanding way to get all the effects of a true, zero-calorie fast.

It wasnt easy, says Aguilar, but it was doable. Im not normally a healthy eater, and I was being given steroids at the time, so my appetite was out of control, but I still managed it because it reduced the pain so much.

Hopefully, patients in several other large studies, all of which are nearing their scheduled completion dates, will comply with fasting protocols well enough to help researchers determine whether short-term fasting can extend life, reduce treatment toxicity or both for patients with glioblastoma, non-small cell lung cancer, lung adenocarcinoma, ovarian cancer, breast cancer and colorectal cancer.

Positive results could change standards of care for all those tumor types within the next couple of years.

For patients who cant wait that long to select their treatment plan, the obvious question is whether they should ask their oncologists about starting now with short- term fasts or the FMD.

Some experts believe its too early to use fasting anywhere outside of clinical trials.Indeed, a group of Italian clinicians recently published a letter in Nature Reviews Cancer that cautioned against what they perceive as excessive enthusiasm about fastings potential benefits and insufficient caution about its potential to harm some patients.

It is worrying that the application of fasting in oncology has been prematurely reported by the media as a potential advance in medical oncology, to the point where FMD kits have recently been commercialized, the clinicians wrote. These may negatively interfere with cancer care, as patients at risk of malnutrition or sarcopenia (muscle loss) could autonomously decrease protein-calorie intake during treatment.

Longo agrees that neither malnourished patients nor those who are responding to their current treatment should try fasting or the FMD outside of clinical trials. However, he believes the data from both animal models and early human trials are strong enough to make fasting an option when approved treatments stop working.

I think (the evidence so far) is enough for an oncologist to say, Look, your therapy isnt working. Im out of options here. This fasting-mimicking diet is so effective in mice. Why dont we give it a shot? You have to understand there are risks, but you also have to understand that were out of options. That conversation would be appropriate now, Longo says.

Fasting isnt the only way to drive blood sugar and insulin down. Patients can achieve nearly equivalent reductions by following a ketogenic diet that provides about 80% of calories from fat, 12% from protein and 8% from carbohydrates.

Low sugar consumption means low blood sugar, which, in turn, means low levels of insulin a hormone secreted by the pancreas to drive sugar into muscles and fuel their growth and/or activity. Healthy tissue, as mentioned before, can adapt to deriving nearly all its energy fromfat, although many people feel pretty drained for a week or so at the beginning of that adjustment. (This lousy feeling is known as keto flu.) Many tumors, on the other hand, seem far less able to overcome their dependence on insulin and sugar (aka glucose).

Weve known for 100 years that cancer cells take up glucose at a much higher rate than do the normal tissues from which those cancer cells emerge, says Lewis Cantley, who holds a doctorate in biophysical chemistry and is the Meyer Director of the Sandra and Edward Meyer Cancer Center and a professor of cancer biology in medicine at Weill Cornell Medical College.

This does not mean that patients can starve their tumors to death simply by following ketogenic diets, but it has led many researchers to speculate that adding a ketogenic diet to standard treatment protocols might increase the efficacy of many of those regimens.

It has been difficult to test this theory, however. Because no pharmaceutical company canpatent a ketogenic diet, no one has a financial incentive to spend the millions of dollars that largestudies cost. Instead, studies get funded through the National Institutes of Health and foundation grants. Tests of FMDs face the same issue.

The ketogenic diet also runs into the same problem that makes it hard to test fasting: patient compliance. Indeed, researchers who work for the Department of Veterans Affairs in Pittsburgh enrolled 11 patients with cancer in a 16-week trial of the ketogenic diet. Only four of them actually followed the diet all 16 weeks.

In spite of the challenges, several recent discoveries suggest that ketogenic diets may be particularly helpful for certain cancer treatments helpful enough to drive funding and convince patients to follow the diet.

Cantley discovered a previously unknown link between sugar, insulin and cancer growth more than three decades ago: an enzyme called phosphoinositide 3-kinase (PI3K) that helps drive sugar into cells. Mutations in the genes that regulate PI3K causing an increase in PI3K activity are among the most common of all cancer mutations.

His discovery eventually led to the creation of PI3K- inhibiting medications, three of which have been approved for the treatment of several cancers. But all three have a big drawback.

When you give patients a PI3 kinase inhibitor, which hits the same enzyme that propagates the insulin response, you get the unsurprising result that the patient instantly becomes insulin resistant. Many of the patients in the trials of these drugs had to drop out because of high blood sugar, Cantley says.

Extra insulin, whether created by the body in response to rising blood sugar or deliberately injected, will solve the problem by driving the sugar into muscles, but it also drives sugar into tumors and destroys treatment efficacy.

Cantleys team hypothesized that PI3K inhibitors would be far safer and more effective if used in combination with some tool that would control blood sugar without driving it into tissues. They saw dramatically improved results in mice when they paired PI3K inhibitors with a class of diabetes medications called SGLT2 inhibitors, which reduce the bodys absorption of glucose via the kidneys so that excess glucose is excreted through the urine. Results were better still when they fed mice a ketogenic diet.

Blood sugar levels hardly went up. Insulin levels hardly went up. Tumors melted away, says Cantley, who also has a financial interest in a company that makes prepackaged meals for patients with cancer. Every tumor we tried essentially disappeared whenever we gave a PI3 kinase inhibitor with a ketogenic diet.

A large human trial will compare the current standard for using PI3K inhibitors against treatment plans that combine PI3K inhibitors with either SGLT2 inhibitors or a ketogenic diet. The ongoing global pandemic delayed the trial for several months, but enrollment has now begun.

And its not the only trial thats testing the ketogenic diets effect on cancer treatments. At least 18 other such studies are either recruiting patients or preparing to do so.

The whole thing comes down to energy. Without energy, nothing can grow, says Thomas N. Seyfried, who holds a doctorate in genetics and biochemistry and is a biology professor at Boston College who studies how metabolic therapies such as a ketogenic diet can affect cancer and other diseases. Tumor cells make energy by fermenting glucose and the amino acid glutamine. If we restrict the availability of glucose and glutamine, this will create tremendous metabolic stress on the tumor cells.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

Read more:
Early Evidence Shows Fasting, Keto Diet May Make Chemo and Some Other Cancer Treatments More Effective and Easier to Tolerate - Curetoday.com

Researchmoz Presents Healthcare Business Process Outsourcing Market Size, Status and Forecast 2020-2026 New Document to its Studies Database

This report, which has been published, is having a meaningful Healthcare Business Process Outsourcing market insight. It casts some lights on industry products and services. Along with those product applications, it also examined whether it reaches up to the end-users or not. This report on this Healthcare Business Process Outsourcing market has given an overall view of the recent technologies used and technological improvements. It also focuses on recent industry trends and which products are quite demanding from a customers perspective. This report is focused on every aspect of the forecast year 2026.

Healthcare Business Process Outsourcing Market dynamics analysis

This report is representing a whole market scenario on a global basis. In this report, we can also find the analysis growth of industries. Through this report, we can easily interpreter the level of market competition, different pricing models, the latest market trends, customer demand, etc. This report acknowledges the revenue model and market expansion of this Healthcare Business Process Outsourcing market. If you want to get that full market information, then this report can help you. It also gives a comprehensive knowledge about the demand and supply graph. Suppose that demand curves moved downward, then from this report, you can know about those factors responsible for its decline. Accordingly, you can know the responsible factors for the rising curve. This Healthcare Business Process Outsourcing market report gives a total knowledge about the market trend and improves its strategies and pricing model.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2812408&source=atm

In the competitive analysis section of the report, leading as well as prominent players of the global Genomic Biomarker market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.The key players covered in this studyBio-RadBeckman CoulterMyriad GeneticsThermo Fisher ScientificRocheQIAGENEpigenomicsAlmacPfizerHuman LongevityValiRxPersonalisEagle GenomicsEmpire GenomicsAgilentIllumina

Research and Methodology

For the research, the Healthcare Business Process Outsourcing markets research teams are adopted various high-end techniques. Industry best analysts are worked on this report. They collected data from various reliable sources and have taken samples of different market segments. They utilize both qualitative and quantitative data in this report. All data are based on primary sources, which are focused on the assessment year 2020-2026. For wise decision-making, they have also done SWOT analysis, which can also help them know their predicted future results. This report also helps to develop Healthcare Business Process Outsourcing market growth by improvising its strategic models.

segment by Type, the product can be split intoOncologyCardiologyNeurologyNephrology

Market segment by Application, split intoHospitalsDiagnostic and research laboratories

Based on regional and country-level analysis, the Genomic Biomarker market has been segmented as follows:North AmericaUnited StatesCanadaEuropeGermanyFranceU.K.ItalyRussiaNordicRest of EuropeAsia-PacificChinaJapanSouth KoreaSoutheast AsiaIndiaAustraliaRest of Asia-PacificLatin AmericaMexicoBrazilMiddle East & AfricaTurkeySaudi ArabiaUAERest of Middle East & Africa

Regional and Country-level Analysis

The Healthcare Business Process Outsourcing market is analysed and market size information is provided by regions (countries).

The key regions covered in the Healthcare Business Process Outsourcing market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2812408&licType=S&source=atm

Table Of Content Covered In this Healthcare Business Process Outsourcing Market Report:

1 Report Overview

2 Global Growth Trends by Regions

3 Competition Landscape by Key Players

4 Breakdown Data by Type (2015-2026)

5 Breakdown Data by Application (2015-2026)

6 North America

7 Europe

8 China

9 Japan

10 Southeast Asia

11 India

12 Central & South America

13Key Players Profiles

14Analysts Viewpoints/Conclusions

NOTE : Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details

Read the original:
Healthcare Business Process Outsourcing Market 2020 Global Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions 2025 - Zenit...

Adipose tissue is rich in multi potent stem cells that have the capability to differentiate into a number of cell types including adipocytes, osteocytes, chondrocytes and others, in vitro. These Adipose Tissue-derived Stem Cells are used for a number of applications including stem cell differentiation studies, regenerative medicine, cell therapy, tissue engineering and development of induced pluripotent stem cell lineage. Adult stem cells such as the Adipose Tissue-derived Stem Cells have a very good potential for regenerative medicine. The Adipose Tissue-derived Stem Cells show higher yields compared with other stem cell sources. Some of the regenerative medicine applications using Adipose Tissue-derived Stem Cells include skin, bone and cartilage regeneration.

For more insights into the Market, request a sample of this report @https://www.persistencemarketresearch.com/samples/25831

Although, Adipose Tissue-derived Stem Cells have the ability to differentiate into different cell types in vitro, unlike the embryonic stem cells they lack the ability to differentiate into all types of organs and tissues of the body. Derivation of stem cells from adipose tissue have a number of advantages including that fat tissue contain 100 to 1000 times more mesenchymal stem cells than the bone marrow. Furthermore the method of collection of fat tissue is relatively easier and is less invasive than that of bone marrow collection. Although Adipose Tissue-derived Stem Cells have a potential to be used in cell-based therapy, there are a number of challenges the Adipose Tissue-derived Stem Cells market has to face. Some of the challenge include the safety issue for the clinical use of Adipose Tissue-derived Stem Cells, development and differentiation of the cells, delivery of the cells in vivo and immune response after the transplant.

For Information On The Research Methodology request here @https://www.persistencemarketresearch.com/methodology/25831

The global Adipose Tissue-derived Stem Cells market is segmented based on product type and end user. Based on product type the Adipose Tissue-derived Stem Cells can be categorized into cell line and reagent & kits. Cell line can be further classified based on the source of the adipose tissue such as human and rodents. Based on reagents the Adipose Tissue-derived Stem Cells market is further classified as media & sera and kits. Based on application the Adipose Tissue-derived Stem Cells market is classified into regenerative medicine, cell therapy, tissue engineering, and other applications such as cell differentiation studies and other similar research. End users of Adipose Tissue-derived Stem Cells market are biotechnology companies and academic and research institutes.

The Global Adipose Tissue-derived Stem Cells market is classified on the basis of product type, end user and region:

Based on the Product Type, Adipose Tissue-derived Stem Cells market is segmented into following:

Based on the application, Adipose Tissue-derived Stem Cells market is segmented into following:

Based on the end user, Adipose Tissue-derived Stem Cells market is segment as below:

To receive extensive list of important regions, Request TOC here @https://www.persistencemarketresearch.com/toc/25831

Growing research activities using stem cells along with the growth of regenerative medicine and cell therapy the global Adipose Tissue-derived Stem Cells market is set to expand considerably during the forecast period. However, ethical concerns and stringent regulations may hinder the growth of the global Adipose Tissue-derived Stem Cells market.

On the basis of geography, global Adipose Tissue-derived Stem Cells market is segmented into six major regions that include North America, Latin America, Europe, Asia-Pacific excluding China, China and Middle East & Africa. North America is expected to be the most lucrative Adipose Tissue-derived Stem Cells market owing to increased research activity of stem cells. Furthermore government support for regenerative and stem cell based studies along with cell therapy studies is driving the growth of the Adipose Tissue-derived Stem Cells market in the region. Changing government regulations in china is supporting the research activity that supports the growth of the adipose tissue-derived stem cell market in the region at a considerable rate.

Key participants operating in the Adipose Tissue-derived Stem Cells market are: Lonza, ThermoFisher Scientific, Celprogen, Inc, American CryoStem, Rexgenero Ltd, iXCells Biotechnologies, Merck KGaA, Lifeline Cell Technology, and others.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Read more:
The Adipose Tissue Derived Stem Cells market to grow in the wake of incorporation of the latest technology - The Think Curiouser

The "Cell Therapy - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

The cell-based markets was analyzed for 2019, and projected to 2029. The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair, as well as diabetes mellitus, will be other major markets.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. The role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering, and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation, and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Story continues

Regulatory and ethical issues involving cell therapy are important and are discussed. The current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 316 of these are profiled in part II of the report along with tabulation of 306 alliances. Of these companies, 171 are involved in stem cells.

Profiles of 73 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 67 Tables and 26 Figures. The bibliography contains 1,200 selected references, which are cited in the text.

Key Topics Covered:

Part I: Technologies, Ethics & Regulations

0. Executive Summary

1. Introduction to Cell Therapy

2. Cell Therapy Technologies

3. Stem Cells

4. Clinical Applications of Cell Therapy

5. Cell Therapy for Cardiovascular Disorders

6. Cell Therapy for Cancer

7. Cell Therapy for Neurological Disorders

8. Ethical, Legal and Political Aspects of Cell therapy

9. Safety and Regulatory Aspects of Cell Therapy

Part II: Markets, Companies & Academic Institutions

10. Markets and Future Prospects for Cell Therapy

11. Companies Involved in Cell Therapy

12. Academic Institutions

13. References

For more information about this report visit https://www.researchandmarkets.com/r/fm571d

Source: Jain PharmaBiotech

View source version on businesswire.com: https://www.businesswire.com/news/home/20201104005266/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See more here:
Global Cell Therapy Technologies, Competitive Landscape & Markets, 2019-2020 & Forecast to 2029 - ResearchAndMarkets.com - Yahoo Finance

MUSC Hollings Cancer Center researchers identified that blocking an alternative energy pathway for T-cells after hematopoietic stem cell transplant helps reduce graft-versus-host disease (GVHD) in an animal model of leukemia.

Xue-Zhong Yu, M.D., who also is associate director of Basic Science at Hollings, and collaborators at the Indiana University School of Medicine discovered that donor T-cells must have the key enzyme lysosomal acid lipase in order to induce GVHD.

The Yu laboratory focuses on understanding the biological balance between GVHD and graft-versus-leukemia effect. Hematopoietic stem cell transplantation is used as a treatment option for some leukemia patients. T-cells in stem cell grafts from a donor are given to a leukemia patient in order to kill the cancer and reboot the patient's immune system. GVHD is a big clinical challenge because the donor T-cells, which come from the bone marrow, can attack the patient's organs. Anywhere from 30% to 70% of patients develop acute GVHD after allogeneic bone marrow transplant and 15% die.

"When we deal with hematopoietic cell transplant, it is an important balance - blocking GVHD while still allowing T-cells to do their job and control the cancer," Yu said.

Each cell in our body has its own metabolic process. Cells convert the food that is eaten into energy in order to perform their intended functions. However, cellular metabolism is often altered in various diseases. Yu researches T-cell metabolism in order to understand the balance between graft-versus-host and graft-versus-leukemia responses.

Most cells in our body require oxygen to create energy efficiently. However, this research focused on lipid, or fat, metabolism. T-cells have special metabolic processes: Sometimes they multiply so rapidly that they need an extra source of energy from free fatty acids.

Lysosomal acid lipase is an enzyme that breaks the large lipids and cholesterol into individual free fatty acid building blocks. If that enzyme is missing, there are not enough free fatty acids for energy production. This changes the T-cell metabolism, which in turn changes T-cell function.

Clinically, broad spectrum immunosuppression drugs (steroids and rapamycin) are still used as the first line of care in patients with severe GVHD. However, Yu and collaborators hypothesized that changing T-cell metabolism could reduce GVHD after hematopoietic stem cell transplantation.

"We know that the gut is the primary organ affected by GVHD. Since the gut has less oxygen, the T-cells rely on free fatty acids and must use lysosomal acid lipase. We thought if we could remove or block the activity of that, we could reduce GVHD in the gut."

The Yu Laboratory collaborated with the Indiana University School of Medicine and used a lysosomal acid lipase-deficient mouse model. T-cells lacking lysosomal acid lipase were given to mice with leukemia. As a control, T-cells with lysosomal acid lipase from normal mice were given to another group of leukemia mice. Strikingly, the mice that received the T-cells without lysosomal acid lipase did not get severe GVHD. Additionally, the T-cells from the donor lysosomal acid lipase-deficient bone marrow still killed the leukemia cells.

To increase the clinical translational potential of the work, orlistat, the FDA-approved lysosomal acid lipase inhibitor was also tested in the leukemia model. Mice with leukemia were treated with orlistat every other day after receiving bone marrow from normal mouse donors. Similar to the first experiment with the lysosomal acid lipase-deficient bone marrow, blocking the activity of lysosomal acid lipase with orlistat greatly reduced GVHD while the graft-versus-leukemia effect was preserved.

Additionally, the researchers discovered that inhibiting the lysosomal acid lipase enzyme with orlistat reduced the number of pathogenic T-cells and increased the number of regulatory T-cells. The pathogenic T-cells are the ones that cause GVHD. Regulatory T-cells are one of the "braking mechanisms" of the immune system. They help to reduce the activity of the pathogenic T-cells and prevent GVHD damage.

Therefore, blocking lysosomal acid lipase activity with orlistat preferentially stopped the donor T-cells from damaging the gut but allowed the T-cells to function during circulation and kill the leukemia cells.

The researchers' future plan is to look deeper at the biological mechanisms. For example, it is not clear how the loss or inhibition of lysosomal acid lipase affects the other metabolites in T-cells. To move this finding closer to the clinic, Yu explained that human cells can be used in a special mouse model that recreates the human immune environment.

"Looking at the immune cells in the gut was technically challenging. However, the results were exciting because our hypothesis was validated. These results encourage us to continue studying this in order to provide better treatment options to patients."

See original here:
Blocking energy pathway reduces GVHD while retaining anti-cancer effects of T-cells - Science Codex

Some people seem to be born with a happier, carefree disposition than others, and research indicates that yes some of your sense of well-being may be in your genes. But only partly.

Your genes make up an estimated 40% of your ability to be happy, says psychotherapist Susan Zinn of Susan Zinn Therapy in Santa Monica, California.

But that doesn't mean that if you weren't born with certain genes, you're destined to be unhappy. Zinn says that "it's completely possible to rewire our brains for happiness," because the other 60% of happiness comes down to lifestyle and other environmental factors.

Learn more about how your genetic makeup contributes to your life satisfaction and how you can increase feelings of happiness and well-being regardless of what your genetic sequence might say about you.

Happiness is typically determined by three main components, according to Zinn:

Research indicates that we can inherit many traits including optimism, self-esteem, and happiness. So by that logic, yes, there are genes that may predispose you to a happier disposition.

For example, a 2011 study found promising evidence that people with a certain form of the gene called 5-HTTLPR reported higher life satisfaction.

And a landmark study in 2016 that formally linked happiness to genetics involved the DNA of nearly 300,000 people. The researchers pinpointed three specific genetic variants associated with well-being. But they also found that these genetic variations weren't the only factor. An interplay of genetics and environment also contributed to happiness.

Despite your genetic makeup, there are ways you can learn to be happier, even in difficult times. Other traits, such as resilience, can be cultivated over time.

"You have a choice," Zinn says. "It's no different than deciding what to wear or what food to order. When it comes to happiness, there's a lot we can do about it."

One way to achieve a happier state is to let go of a quest for perfectionism that focuses only on the end goal of success, Zinn says. Linking happiness with perfectionism and success is common in American culture, but it leads you to concentrate on the summit of what you want to achieve rather than the journey of what happens along the way.

Here are some other practical ways to choose happiness:

Although research suggests that happiness is inherited to some extent, you're not limited by your DNA. The ability to feel happy takes practice and can be achieved with the right mindset.

Volunteering, exercise, nature, and attention to gratitude practices are just a few things you can do to increase your sense of life satisfaction, well-being, purpose, and ultimately, happiness.

Read the rest here:
Scientists think about 40% of happiness is genetic while the rest comes down to 3 main components - Insider - INSIDER